Table 3. Oligonucleotides used in EMSA, introduced mutations are underlined.

Description	Oligonucleotides	Sense (5′->3′)	Antisense (5′->3′)
E2F/NF-e/c-Myb and TCF μ/PU.1/ELF1 binding sites (−45 to 0)	lil157-158	CCCTCTCAGGGCGACATTACAGGCAAAGAAGAGGAAGTGGTAGC	GCTACCACTTCCTCTTCTTTGCCTGTAACTGTCGCCCTGAGAGGG
−27–28 TT>AA substitution (−45 to 0)	lil159-160	CCCTCTCAGGGCGACAGAAACAGGCAAAGAAGAGGAAGTGGTAGC	GCTACCACTTCCTCTTCTTTGCCTGTTTCTGTCGCCCTGAGAGGG
−32–33 GA>AC substitution (−45 to 0)	lil161-162	CCCTCTCAGGGCACCAGTTACAGGCAAAGAAGAGGAAGTGGTAGC	GCTACCACTTCCTCTTCTTTGCCTGTAACTGGTGCCCTGAGAGGG
E2F/NF-e/c-Myb binding site (−39 to −22)	lil87-88	CAGGGCGACAGTTACAGG	CCTGTAACTGTCGCCCTG
−27–28 TT>AA substitution (−39 to −22)	lil89-90	CAGGGCGACAGAAACAGG	CCTGTTTCTGTCGCCCTG
−32–33 GA>AC substitution (−39 to −22)	lil147-148	CAGGGCACCAGTTACAGG	CCTGTAACTGGTGCCCTG
Sp1 binding site (−160 to −141)	lil79- 80	GTGTCGAGTGGGCGGAAGAA	TTCTTCCGCCCACTCGACAC
CpG 3+4 methylated (−160 to −141)	lil85-86	GTGTmetCGAGTGGGmetCGGAAGAA	TTCTTmetCCGCCCACTmetCGACAC
CpG3 methylated (−160 to −141)	lil81-84	GTGTmetCGAGTGGGCGGAAGAA	TTCTTCCGCCCACTmetCGACAC
CpG4 methylated (−160 to −141)	lil82-83	GTGTCGAGTGGGmetCGGAAGAA	TTCTTCmetCGCCCACTCGACAC